Myriad’s BRACAnalysis CDx to be used in PROfound Clinical Trial

Myriad’s BRACAnalysis CDx is an in-vitro diagnostic device that detects mutations in BRCA1 and BRCA2 genes. Credit: Myriad Genetics.



  • Myriad deepens collaboration with AstraZeneca and Merck